The U.S. Food and Drug Administration (FDA) has approved Epkinly (epcoritamab-bysp) plus Revlimid (lenalidomide) and Rituxan ...
WASHINGTON (Reuters) - Survival rates have improved in the United States for children with three common types of blood cancer since the 1990s, thanks to improved treatment, researchers in Germany said ...
ROCHESTER, N.Y. (WROC) — A groundbreaking Hodgkin lymphoma study from the University of Rochester Medical Center showed a 92% survival rate with fewer side effects and reduced radiation therapy use.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback